Table 2 HKDC1-based peptides induce cell death in different cancer cell lines.
Cell line | Cell type/EBV(+/−) | Peptide IC50 (µM) | |
|---|---|---|---|
Tf-D-HKC15 | Tf-D-HKC8 | ||
HMECs | Human mammary epithelial cells/EBV(−) | >15.0 (n = 3) | >15.0 (n = 3) |
Healthy MNCs | Healthy human mononuclear cells/EBV(−) | >15.0 (n = 3) | >15.0 (n = 3) |
SNK6 | Human natural killer/T-cell lymphoma/EBV(+) | 1.2 ± 0.3 (n = 3) | 0.3 ± 0.2 (n = 5) |
HANK1 | Human natural killer/T-cell lymphoma/EBV(+) | 1.4 ± 0.6 (n = 3) | 0.7 ± 0.4 (n = 3) |
SNT8 | Human natural killer/T-cell lymphoma/EBV(+) | 1.1 ± 0.4 (n = 3) | 0.6 ± 0.3 (n = 3) |
Namalwa | Human Burkitt’s lymphoma/EBV(+) | 0.9 ± 0.3 (n = 3) | 0.7 ± 0.4 (n = 3) |
NK92 | Human natural killer non-Hodgkin’s lymphoma/EBV(−) | 1.5 ± 0.6 (n = 3) | 0.9 ± 0.4 (n = 3) |
MM.1R | Human B lymphoblast/EBV(−) | 2.3 ± 0.7 (n = 3) | 1.6 ± 0.4 (n = 3) |
U266B1 | Human B lymphoblast/EBV(−) | 2.2 ± 0.6 (n = 3) | 1.4 ± 0.3 (n = 3) |
RPMI 8226 | Human B lymphoblast/EBV(−) | 1.9 ± 0.7 (n = 3) | 1.3 ± 0.6 (n = 3) |
Kasumi-1 | Human acute myeloblastic leukemia/EBV(−) | 2.7 ± 0.9 (n = 3) | 1.8 ± 0.6 (n = 3) |
HL-60 | Human acute promyelocytic leukemia/EBV(−) | 2.2 ± 0.6 (n = 3) | 1.7 ± 0.4 (n = 3) |
THP1 | Human monocytic leukemia/EBV(−) | 2.3 ± 0.5 (n = 3) | 1.8 ± 0.6 (n = 3) |
MCF7 | Human breast adenocarcinoma/EBV(−) | >15.0 (n = 3) | >15.0 (n = 3) |
MDA-MB-231 | Human breast adenocarcinoma/EBV(−) | 14.4 ± 0.8 (n = 3) | 11.6 ± 1.1 (n = 3) |
SW480 | Human colorectal adenocarcinoma/EBV(−) | 8.9 ± 0.9 (n = 3) | 6.7 ± 0.8 (n = 3) |
SW620 | Human colorectal adenocarcinoma/EBV(−) | 12.5 ± 0.8 (n = 3) | 10.2 ± 0.7 (n = 5) |
Hela | Human cervix adenocarcinoma/EBV(−) | 9.8 ± 0.6 (n = 3) | 6.8 ± 0.9 (n = 3) |
HepG2 | Human hepatocellular carcinoma/EBV(−) | >15.0 (n = 3) | >15.0 (n = 3) |
